JP2017518372A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017518372A5 JP2017518372A5 JP2017515026A JP2017515026A JP2017518372A5 JP 2017518372 A5 JP2017518372 A5 JP 2017518372A5 JP 2017515026 A JP2017515026 A JP 2017515026A JP 2017515026 A JP2017515026 A JP 2017515026A JP 2017518372 A5 JP2017518372 A5 JP 2017518372A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- composition
- complementary sequence
- guide rna
- ebv genome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462005395P | 2014-05-30 | 2014-05-30 | |
| US62/005,395 | 2014-05-30 | ||
| US201462029072P | 2014-07-25 | 2014-07-25 | |
| US62/029,072 | 2014-07-25 | ||
| PCT/US2015/033186 WO2015184262A1 (en) | 2014-05-30 | 2015-05-29 | Compositions and methods of delivering treatments for latent viral infections |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017518372A JP2017518372A (ja) | 2017-07-06 |
| JP2017518372A5 true JP2017518372A5 (enExample) | 2018-07-05 |
Family
ID=53366336
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017515025A Pending JP2017518075A (ja) | 2014-05-30 | 2015-05-29 | 潜伏性ウイルス感染を処置するための組成物および方法 |
| JP2017515026A Pending JP2017518372A (ja) | 2014-05-30 | 2015-05-29 | 潜伏性ウイルス感染用の処置剤を送達するための組成物および方法 |
| JP2019205922A Pending JP2020043862A (ja) | 2014-05-30 | 2019-11-14 | 潜伏性ウイルス感染を処置するための組成物および方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017515025A Pending JP2017518075A (ja) | 2014-05-30 | 2015-05-29 | 潜伏性ウイルス感染を処置するための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019205922A Pending JP2020043862A (ja) | 2014-05-30 | 2019-11-14 | 潜伏性ウイルス感染を処置するための組成物および方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (7) | US20160060655A1 (enExample) |
| EP (3) | EP3149169A1 (enExample) |
| JP (3) | JP2017518075A (enExample) |
| KR (1) | KR20170005494A (enExample) |
| CN (2) | CN107002094A (enExample) |
| AU (3) | AU2015266776A1 (enExample) |
| BR (1) | BR112016028023A2 (enExample) |
| CA (2) | CA2949713A1 (enExample) |
| SG (1) | SG11201610028TA (enExample) |
| WO (3) | WO2015184262A1 (enExample) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013066438A2 (en) | 2011-07-22 | 2013-05-10 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| WO2014113493A1 (en) | 2013-01-16 | 2014-07-24 | Emory University | Cas9-nucleic acid complexes and uses related thereto |
| DK3456831T3 (da) | 2013-04-16 | 2021-09-06 | Regeneron Pharma | Målrettet modifikation af rottegenom |
| US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| AU2014312123A1 (en) * | 2013-08-29 | 2016-03-17 | Temple University Of The Commonwealth System Of Higher Education | Methods and compositions for RNA-guided treatment of HIV infection |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| MX388127B (es) | 2013-12-11 | 2025-03-19 | Regeneron Pharma | Metodos y composiciones para la modificacion dirigida de un genoma. |
| US20150166984A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting alpha-antitrypsin point mutations |
| WO2015184262A1 (en) | 2014-05-30 | 2015-12-03 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods of delivering treatments for latent viral infections |
| AU2015298571B2 (en) | 2014-07-30 | 2020-09-03 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| EP3221457B1 (en) | 2014-11-21 | 2019-03-20 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for targeted genetic modification using paired guide rnas |
| CA2969619A1 (en) | 2014-12-03 | 2016-06-09 | Agilent Technologies, Inc. | Guide rna with chemical modifications |
| US10059940B2 (en) * | 2015-01-27 | 2018-08-28 | Minghong Zhong | Chemically ligated RNAs for CRISPR/Cas9-lgRNA complexes as antiviral therapeutic agents |
| CN107787367B (zh) | 2015-04-06 | 2021-10-26 | 里兰斯坦福初级大学理事会 | 用于crispr/cas介导的基因调控的化学修饰的引导rna |
| US20160348074A1 (en) * | 2015-05-29 | 2016-12-01 | Agenovir Corporation | Methods and compositions for treating cells for transplant |
| US10117911B2 (en) | 2015-05-29 | 2018-11-06 | Agenovir Corporation | Compositions and methods to treat herpes simplex virus infections |
| US20160346362A1 (en) * | 2015-05-29 | 2016-12-01 | Agenovir Corporation | Methods and compositions for treating cytomegalovirus infections |
| EP3324999A1 (en) * | 2015-05-29 | 2018-05-30 | Agenovir Corporation | Compositions and methods for cell targeted hpv treatment |
| CA2999922A1 (en) * | 2015-09-29 | 2017-04-06 | Agenovir Corporation | Delivery methods and compositions |
| JP7059179B2 (ja) | 2015-10-20 | 2022-04-25 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 遺伝子操作のための方法及び製品 |
| WO2017070632A2 (en) | 2015-10-23 | 2017-04-27 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
| CN108473527A (zh) * | 2015-12-09 | 2018-08-31 | 切除生物治疗公司 | 用于消除免疫抑制疗法期间jc病毒激活和pml(进行性多灶性白质脑病)风险的基因编辑方法和组合物 |
| EP3407918A4 (en) * | 2016-01-25 | 2019-09-04 | Excision Biotherapeutics | METHOD AND COMPOSITIONS FOR RNA-TREATED TREATMENT OF HIV INFECTIONS |
| US20190038770A1 (en) * | 2016-01-25 | 2019-02-07 | Excision Biotherapeutics,Inc. | Rna guided eradication of human jc virus and other polyomaviruses |
| US20170246260A1 (en) * | 2016-02-25 | 2017-08-31 | Agenovir Corporation | Modified antiviral nuclease |
| AU2017223964A1 (en) * | 2016-02-25 | 2018-09-06 | Agenovir Corporation | Viral and oncoviral nuclease treatment |
| EP3448987A4 (en) | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| US20190093092A1 (en) * | 2016-05-05 | 2019-03-28 | Temple University - Of The Commonwealth System Of Higher Education | Rna guided eradication of varicella zoster virus |
| JP2019519250A (ja) * | 2016-05-10 | 2019-07-11 | ユナイテッド ステイツ ガバメント アズ リプレゼンテッド バイ ザ デパートメント オブ ベテランズ アフェアーズＵｎｉｔｅｄ Ｓｔａｔｅｓ Ｇｏｖｅｒｎｍｅｎｔ Ａｓ Ｒｅｐｒｅｓｅｎｔｅｄ Ｂｙ Ｔｈｅ Ｄｅｐａｒｔｍｅｎｔ Ｏｆ Ｖｅｔｅｒａｎｓ Ａｆｆａｉｒｓ | Ｈｉｖ−１感染と複製に必須な遺伝子を切断するｃｒｉｓｐｒ／ｃａｓの構築物のレンチウィルスによる送達 |
| SG10202102885UA (en) | 2016-05-20 | 2021-05-28 | Regeneron Pharma | Methods for breaking immunological tolerance using multiple guide rnas |
| RU2018144745A (ru) * | 2016-06-01 | 2020-07-09 | Эксижн Биотерапьютикс, Инк. | Композиции и способы лечения, направленные на литические и лизогенные вирусы |
| US10767175B2 (en) | 2016-06-08 | 2020-09-08 | Agilent Technologies, Inc. | High specificity genome editing using chemically modified guide RNAs |
| CA3027428A1 (en) * | 2016-06-14 | 2017-12-21 | Regents Of The University Of Minnesota | Genetically modified cells, tissues, and organs for treating disease |
| WO2018027078A1 (en) | 2016-08-03 | 2018-02-08 | President And Fellows Of Harard College | Adenosine nucleobase editors and uses thereof |
| AU2017308889B2 (en) | 2016-08-09 | 2023-11-09 | President And Fellows Of Harvard College | Programmable Cas9-recombinase fusion proteins and uses thereof |
| WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| WO2018045284A1 (en) * | 2016-09-02 | 2018-03-08 | The General Hospital Corporation | Methods and systems for non-contact construction of an internal structure |
| KR20230010826A (ko) | 2016-10-14 | 2023-01-19 | 프리시젼 바이오사이언시스 인코포레이티드 | B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제 |
| KR20240007715A (ko) | 2016-10-14 | 2024-01-16 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵염기 에디터의 aav 전달 |
| WO2018112225A1 (en) * | 2016-12-14 | 2018-06-21 | The J. David Gladstone Institutes | Methods and compositions for generating a deletion library and for identifying a defective interfering particle (dip) |
| CN106729753A (zh) * | 2016-12-16 | 2017-05-31 | 谭旭 | 抗乙型肝炎病毒的递送系统和生物制剂 |
| WO2018118586A1 (en) * | 2016-12-22 | 2018-06-28 | Agenovir Corporation | Antiviral/endogenous combination therapy |
| WO2018118587A1 (en) * | 2016-12-22 | 2018-06-28 | Agenovir Corporation | Modified polynucleotides for antiviral therapy |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| US20180201921A1 (en) * | 2017-01-18 | 2018-07-19 | Excision Biotherapeutics, Inc. | CRISPRs |
| US20190071673A1 (en) * | 2017-01-18 | 2019-03-07 | Thomas Malcolm | CRISPRs WITH IMPROVED SPECIFICITY |
| WO2018140269A1 (en) * | 2017-01-26 | 2018-08-02 | Excision Biotherapeutics, Inc. | Lentivirus and non-integrating lentivirus as viral vector to deliver crispr therapeutic |
| KR20190123328A (ko) | 2017-03-09 | 2019-10-31 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 암 백신 |
| WO2018165504A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| CN110914310A (zh) | 2017-03-10 | 2020-03-24 | 哈佛大学的校长及成员们 | 胞嘧啶至鸟嘌呤碱基编辑器 |
| IL306092A (en) | 2017-03-23 | 2023-11-01 | Harvard College | Nucleic base editors that include nucleic acid programmable DNA binding proteins |
| US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| EP3635121A1 (en) * | 2017-06-02 | 2020-04-15 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Viral vector combining gene therapy and genome editing approaches for gene therapy of genetic disorders |
| EP3658573A1 (en) | 2017-07-28 | 2020-06-03 | President and Fellows of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace) |
| JP2020533968A (ja) * | 2017-08-25 | 2020-11-26 | オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 組換えアデノ随伴ベクター |
| EP3676376B1 (en) | 2017-08-30 | 2025-01-15 | President and Fellows of Harvard College | High efficiency base editors comprising gam |
| CA3082251A1 (en) | 2017-10-16 | 2019-04-25 | The Broad Institute, Inc. | Uses of adenosine base editors |
| US12406749B2 (en) | 2017-12-15 | 2025-09-02 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| WO2019204210A1 (en) * | 2018-04-16 | 2019-10-24 | Georgia Tech Research Corporation | Mrna driven expression of rna editors for treatment of pathologies |
| WO2019226953A1 (en) | 2018-05-23 | 2019-11-28 | The Broad Institute, Inc. | Base editors and uses thereof |
| EP3820495A4 (en) | 2018-07-09 | 2022-07-20 | The Broad Institute Inc. | RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| CN109943563A (zh) * | 2019-03-08 | 2019-06-28 | 内蒙古大学 | CRISPR-Cas9系统介导的狂犬病病毒基因组敲除的方法 |
| WO2020191241A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| WO2020214842A1 (en) | 2019-04-17 | 2020-10-22 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| US12614611B2 (en) * | 2019-06-06 | 2026-04-28 | Tata Consultancy Services Limited | Method and system for identification of candidate target sites for combating pathogens |
| CN112168808B (zh) * | 2019-07-02 | 2023-01-24 | 深圳市第二人民医院 | 一种基于crispr的细胞核靶向药物递送系统 |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| US12410418B2 (en) | 2019-12-06 | 2025-09-09 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| CA3177481A1 (en) | 2020-05-08 | 2021-11-11 | David R. Liu | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
| WO2021252733A2 (en) | 2020-06-10 | 2021-12-16 | Bonadea Diagnostics, Llc | Sequence conversion reaction |
| CN112795696A (zh) * | 2020-12-31 | 2021-05-14 | 北京思尔成生物技术有限公司 | 乙型肝炎病毒pgRNA芯片数字PCR绝对定量检测试剂盒及方法 |
| WO2022261150A2 (en) | 2021-06-09 | 2022-12-15 | Scribe Therapeutics Inc. | Particle delivery systems |
| WO2023039586A1 (en) | 2021-09-10 | 2023-03-16 | Agilent Technologies, Inc. | Guide rnas with chemical modification for prime editing |
| CN114196556B (zh) * | 2021-12-31 | 2023-08-01 | 重庆大学 | 一种高毒力蝗绿僵菌菌株及其构建方法 |
| CN117065052A (zh) * | 2022-05-16 | 2023-11-17 | 上海行深生物科技有限公司 | 递送自复制rna分子的方法 |
| JP2026523341A (ja) | 2023-05-15 | 2026-07-14 | エヌクロマ・バイオ，インコーポレーテッド | Ｈｂｖ遺伝子発現のエピジェネティック調節のための組成物および方法 |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1003131A (en) * | 1910-08-17 | 1911-09-12 | Leonard F Bellingrath | Valve operating and indicating mechanism. |
| US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US5208036A (en) | 1985-01-07 | 1993-05-04 | Syntex (U.S.A.) Inc. | N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| AU7979491A (en) | 1990-05-03 | 1991-11-27 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
| US5580571A (en) | 1991-10-15 | 1996-12-03 | Hostetler; Karl Y. | Nucleoside analogues |
| SE9200951D0 (sv) | 1992-03-27 | 1992-03-27 | Kabi Pharmacia Ab | Pharmaceutical composition containing a defined lipid system |
| US5356802A (en) | 1992-04-03 | 1994-10-18 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease |
| US5436150A (en) | 1992-04-03 | 1995-07-25 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease |
| US5487994A (en) | 1992-04-03 | 1996-01-30 | The Johns Hopkins University | Insertion and deletion mutants of FokI restriction endonuclease |
| CA2135646A1 (en) * | 1992-05-11 | 1993-11-25 | Kenneth G. Draper | Method and reagent for inhibiting viral replication |
| JPH09500013A (ja) | 1993-06-01 | 1997-01-07 | ライフ・テクノロジーズ・インコーポレイテッド | カチオン性脂質による遺伝子免疫 |
| US6242568B1 (en) | 1994-01-18 | 2001-06-05 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
| US6140466A (en) | 1994-01-18 | 2000-10-31 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
| CA2196419C (en) | 1994-08-20 | 2007-08-21 | Yen Choo | Improvements in or relating to binding proteins for recognition of dna |
| US5789538A (en) | 1995-02-03 | 1998-08-04 | Massachusetts Institute Of Technology | Zinc finger proteins with high affinity new DNA binding specificities |
| US5925523A (en) | 1996-08-23 | 1999-07-20 | President & Fellows Of Harvard College | Intraction trap assay, reagents and uses thereof |
| US6410248B1 (en) | 1998-01-30 | 2002-06-25 | Massachusetts Institute Of Technology | General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites |
| US6383481B1 (en) | 1998-03-30 | 2002-05-07 | Japan Immunoresearch Laboratories Co., Ltd. | Method for transplantation of hemopoietic stem cells |
| US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
| US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| CA2392456A1 (en) | 1999-11-24 | 2001-05-31 | Oklahoma Medical Research Foundation | Assays and therapies for latent viral infection |
| US7740871B2 (en) * | 2002-09-19 | 2010-06-22 | Johns Hopkins University School Of Medicine | Cancer immunotherapy with a viral antigen-defined, immunomodulator-secreting cell vaccine |
| US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
| US7888121B2 (en) * | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| CN1920562A (zh) * | 2003-08-20 | 2007-02-28 | 香港神农有限公司 | Eb病毒蛋白酶联免疫吸附诊断试剂盒及其制备方法 |
| EP1678292A4 (en) * | 2003-09-18 | 2008-05-07 | Univ Emory | IMPROVED MVA VACCINES |
| WO2006070370A2 (en) | 2004-12-29 | 2006-07-06 | Hadasit Medical Research Services & Development Limited | Stem cells culture systems |
| DK3246403T3 (da) * | 2005-10-18 | 2020-10-26 | Prec Biosciences | Rationelt designede meganucleaser med ændret sekvens-specificitet og dna-bindende affinitet |
| US20070196389A1 (en) | 2005-11-18 | 2007-08-23 | The Ohio State University Research Foundation | Viral gene products and methods for vaccination to prevent viral associated diseases |
| GB0526211D0 (en) | 2005-12-22 | 2006-02-01 | Oxford Biomedica Ltd | Viral vectors |
| EP2027262B1 (en) | 2006-05-25 | 2010-03-31 | Sangamo Biosciences Inc. | Variant foki cleavage half-domains |
| US8481506B2 (en) * | 2006-12-05 | 2013-07-09 | Rosetta Genomics, Ltd. | Nucleic acids involved in viral infection |
| US20100076057A1 (en) | 2008-09-23 | 2010-03-25 | Northwestern University | TARGET DNA INTERFERENCE WITH crRNA |
| US20110023144A1 (en) | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genomic editing of genes involved in amyotrophyic lateral sclerosis disease |
| CN101880649B (zh) | 2009-05-05 | 2012-09-05 | 中国福利会国际和平妇幼保健院 | 一种干细胞培养方法 |
| US10238734B2 (en) * | 2010-03-23 | 2019-03-26 | The Regents Of The University Of California | Compositions and methods for self-adjuvanting vaccines against microbes and tumors |
| US9637739B2 (en) | 2012-03-20 | 2017-05-02 | Vilnius University | RNA-directed DNA cleavage by the Cas9-crRNA complex |
| WO2013141680A1 (en) | 2012-03-20 | 2013-09-26 | Vilnius University | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX |
| CN103361328B (zh) * | 2012-03-30 | 2017-08-18 | 复旦大学 | 介导整合的hiv‑1前病毒基因敲除的锌指核酸内切酶及其制法和应用 |
| ES2728782T3 (es) | 2012-05-25 | 2019-10-28 | Univ California | Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN |
| WO2013188037A2 (en) | 2012-06-11 | 2013-12-19 | Agilent Technologies, Inc | Method of adaptor-dimer subtraction using a crispr cas6 protein |
| US20150315576A1 (en) * | 2012-11-01 | 2015-11-05 | Massachusetts Institute Of Technology | Genetic device for the controlled destruction of dna |
| WO2014093479A1 (en) | 2012-12-11 | 2014-06-19 | Montana State University | Crispr (clustered regularly interspaced short palindromic repeats) rna-guided control of gene regulation |
| MX380562B (es) | 2012-12-12 | 2025-03-12 | Broad Inst Inc | Modificaciones de sistemas, métodos y composiciones guía optimizadas para la manipulación de secuencias. |
| CN105209621B (zh) | 2012-12-12 | 2021-05-25 | 布罗德研究所有限公司 | 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化 |
| SG10201707569YA (en) * | 2012-12-12 | 2017-10-30 | Broad Inst Inc | Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications |
| PT2931898E (pt) | 2012-12-12 | 2016-06-16 | Harvard College | Manipulação e otimização de sistemas, métodos e composições para manipulação de sequências com domínios funcionais |
| US8697359B1 (en) * | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| EP3064585B1 (en) | 2012-12-12 | 2020-02-05 | The Broad Institute, Inc. | Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation |
| IL308158A (en) | 2012-12-17 | 2023-12-01 | Harvard College | Rna-guided human genome engineering |
| WO2014113493A1 (en) | 2013-01-16 | 2014-07-24 | Emory University | Cas9-nucleic acid complexes and uses related thereto |
| WO2014124226A1 (en) | 2013-02-07 | 2014-08-14 | The Rockefeller University | Sequence specific antimicrobials |
| WO2014143381A1 (en) | 2013-03-09 | 2014-09-18 | Agilent Technologies, Inc. | Methods of in vivo engineering of large sequences using multiple crispr/cas selections of recombineering events |
| ES2749624T3 (es) | 2013-03-14 | 2020-03-23 | Caribou Biosciences Inc | Composiciones y métodos de ácidos nucleicos dirigidos a ácido nucleico |
| CN105408483A (zh) | 2013-03-15 | 2016-03-16 | 通用医疗公司 | 遗传和表观遗传调节蛋白至特定基因组基因座的rna引导的靶向 |
| US20140349400A1 (en) | 2013-03-15 | 2014-11-27 | Massachusetts Institute Of Technology | Programmable Modification of DNA |
| US9234213B2 (en) | 2013-03-15 | 2016-01-12 | System Biosciences, Llc | Compositions and methods directed to CRISPR/Cas genomic engineering systems |
| US20140273230A1 (en) | 2013-03-15 | 2014-09-18 | Sigma-Aldrich Co., Llc | Crispr-based genome modification and regulation |
| ES2747833T3 (es) | 2013-04-04 | 2020-03-11 | Dartmouth College | Composiciones y procedimientos para la escisión in vivo del ADN proviral del vih-1 |
| WO2014172470A2 (en) | 2013-04-16 | 2014-10-23 | Whitehead Institute For Biomedical Research | Methods of mutating, modifying or modulating nucleic acid in a cell or nonhuman mammal |
| EP2997146A4 (en) | 2013-05-15 | 2017-04-26 | Sangamo BioSciences, Inc. | Methods and compositions for treatment of a genetic condition |
| US9873907B2 (en) | 2013-05-29 | 2018-01-23 | Agilent Technologies, Inc. | Method for fragmenting genomic DNA using CAS9 |
| KR20260047646A (ko) | 2013-07-09 | 2026-04-08 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 멀티플렉스 rna-가이드된 게놈 조작 |
| EP3022304B1 (en) | 2013-07-19 | 2018-12-26 | Larix Biosciences LLC | Methods and compositions for producing double allele knock outs |
| AU2014312123A1 (en) | 2013-08-29 | 2016-03-17 | Temple University Of The Commonwealth System Of Higher Education | Methods and compositions for RNA-guided treatment of HIV infection |
| EP4074330A1 (en) | 2013-09-05 | 2022-10-19 | Massachusetts Institute of Technology | Tuning microbial populations with programmable nucleases |
| CN111218447B (zh) | 2013-11-07 | 2024-10-11 | 爱迪塔斯医药有限公司 | 使用统治型gRNA的CRISPR相关方法和组合物 |
| CN105899658B (zh) * | 2013-12-12 | 2020-02-18 | 布罗德研究所有限公司 | 针对hbv和病毒性疾病以及障碍的crispr-cas系统和组合物的递送、用途和治疗应用 |
| WO2015089419A2 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components |
| US9476065B2 (en) | 2013-12-19 | 2016-10-25 | Amyris, Inc. | Methods for genomic integration |
| WO2015126927A2 (en) | 2014-02-18 | 2015-08-27 | Duke University | Compositions for the inactivation of virus replication and methods of making and using the same |
| WO2015153889A2 (en) | 2014-04-02 | 2015-10-08 | University Of Florida Research Foundation, Incorporated | Materials and methods for the treatment of latent viral infection |
| CN103911376B (zh) * | 2014-04-03 | 2017-02-15 | 黄行许 | CRISPR‑Cas9靶向敲除乙肝病毒cccDNA及其特异性sgRNA |
| WO2015184262A1 (en) | 2014-05-30 | 2015-12-03 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods of delivering treatments for latent viral infections |
-
2015
- 2015-05-29 WO PCT/US2015/033186 patent/WO2015184262A1/en not_active Ceased
- 2015-05-29 AU AU2015266776A patent/AU2015266776A1/en not_active Abandoned
- 2015-05-29 EP EP15727838.3A patent/EP3149169A1/en not_active Withdrawn
- 2015-05-29 CA CA2949713A patent/CA2949713A1/en not_active Abandoned
- 2015-05-29 CA CA2949710A patent/CA2949710A1/en not_active Abandoned
- 2015-05-29 BR BR112016028023A patent/BR112016028023A2/pt not_active Application Discontinuation
- 2015-05-29 KR KR1020167036734A patent/KR20170005494A/ko not_active Withdrawn
- 2015-05-29 JP JP2017515025A patent/JP2017518075A/ja active Pending
- 2015-05-29 WO PCT/US2015/033199 patent/WO2015184268A1/en not_active Ceased
- 2015-05-29 CN CN201580028992.1A patent/CN107002094A/zh active Pending
- 2015-05-29 AU AU2015266767A patent/AU2015266767A1/en not_active Abandoned
- 2015-05-29 US US14/725,888 patent/US20160060655A1/en not_active Abandoned
- 2015-05-29 WO PCT/US2015/033180 patent/WO2015184259A1/en not_active Ceased
- 2015-05-29 EP EP15729007.3A patent/EP3149170A1/en not_active Withdrawn
- 2015-05-29 AU AU2015266770A patent/AU2015266770A1/en not_active Abandoned
- 2015-05-29 JP JP2017515026A patent/JP2017518372A/ja active Pending
- 2015-05-29 CN CN201580029041.6A patent/CN106574256A/zh active Pending
- 2015-05-29 US US14/725,943 patent/US10066241B2/en not_active Expired - Fee Related
- 2015-05-29 EP EP15729008.1A patent/EP3149171A1/en not_active Withdrawn
- 2015-05-29 SG SG11201610028TA patent/SG11201610028TA/en unknown
- 2015-07-02 US US14/790,748 patent/US9487802B2/en not_active Expired - Fee Related
-
2016
- 2016-11-28 US US15/362,519 patent/US20170182190A1/en not_active Abandoned
-
2018
- 2018-01-23 US US15/877,996 patent/US20190010518A1/en not_active Abandoned
- 2018-03-20 US US15/926,688 patent/US20190032090A1/en not_active Abandoned
- 2018-07-26 US US16/046,083 patent/US20190185882A1/en not_active Abandoned
-
2019
- 2019-11-14 JP JP2019205922A patent/JP2020043862A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017518075A5 (enExample) | ||
| US11273209B2 (en) | Methods and compositions for RNA-guided treatment of HIV infection | |
| JP7522088B2 (ja) | 単純ヘルペス１型および他の関連するヘルペスウイルスのｒｎａガイド除去 | |
| JP7176737B2 (ja) | レトロウイルス核酸配列の切除 | |
| US20170247703A1 (en) | Antiviral nuclease methods | |
| US20180303915A1 (en) | Methods and compositions for rna-guided treatment of hiv infection | |
| JP2012509340A5 (enExample) | ||
| EP3407918A1 (en) | Methods and compositions for rna-guided treatment of hiv infection | |
| KR20170005494A (ko) | 잠복 바이러스 감염에 대한 치료제를 전달하는 조성물 및 방법 | |
| WO2009012143A3 (en) | Virus derived antimicrobial peptides | |
| EP4600366A3 (en) | Cas 9 retroviral integrase systems for targeted incorporation of a dna sequence into a genome of a cell | |
| JP2010539901A5 (enExample) | ||
| CN108103094B (zh) | 用于靶向抑制hiv-1前病毒表达的表达载体及其制备方法和应用 | |
| WO2013037841A3 (fr) | Genomes lentiviraux chimeriques non- integratifs comme vaccins contre hiv-1 | |
| Azevedo-Pereira et al. | Inhibition of HIV replication by host cellular factors | |
| De Clercq | Status presens of antiviral drugs and strategies: Part II: RNA VIRUSES (EXCEPT RETROVIRUSES) | |
| De Clercq | Status presens of antiviral drugs and strategies: Part I: DNA viruses and retroviruses | |
| Sheikholeslami et al. | Variant Cells and Viral Infections: Understanding Cellular Coping Mechanisms | |
| Falqui | Development of poxvirus-derived vectors to analyze novel ISG15 functions | |
| WO2022256516A2 (en) | Gene editing therapy for hiv infection via dual targeting of hiv genome and ccr5 | |
| WO2005100383A3 (en) | Novel hiv+ infected cells targeting retroviral vectors and uses thereof for treatment of hiv infection | |
| HK40000290A (en) | Excision of retroviral nucleic acid sequences | |
| Hastie | Understanding and overcoming limitations of vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma | |
| JP2010248179A (ja) | 医薬組成物 |